REGN Q2 2018 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

REGNRegeneron Pharmaceuticals, Inc.

$81B

Q2 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1.6B+9.4% YoY

Gross Profit

$1.5B92.2% margin

Operating Income

$622M38.7% margin

Net Income

$551M34.3% margin

EPS (Diluted)

$4.82

QoQ Revenue Growth

+6.4%

Cash Flow

Operating Cash Flow

$395M

Free Cash Flow

$283M

Stock-Based Comp.

$107M

Balance Sheet

Total Assets

$10.0B

Total Liabilities

$2.8B

Stockholders' Equity

$7.2B

Cash & Equivalents

$918M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.6B	$1.5B	+9.4%
Gross Profit	$1.5B	$1.3B	+11.3%
Operating Income	$622M	$550M	+13.1%
Net Income	$551M	$388M	+42.2%

Revenue Segments

Product

$996M100%